BETA vs QMSMEDI: Stock Comparison
BETA DRUGS shows a higher ROCE and a higher net margin, while QMSMEDI shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 4; QMSMEDI leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BETA | QMSMEDI |
|---|---|---|
| Live Price | ₹2,079 | ₹138.13 |
| Day Change | 0.68% | 4.71% |
| Volume | 4,664 | 1.25 L |
| 52-Week High | ₹2,807.9 | ₹140 |
| 52-Week Low | ₹990.1 | ₹98.05 |
| Distance from 52W High | -25.96% | -1.34% |
Valuation
| Metric | BETA | QMSMEDI |
|---|---|---|
| Market Cap | ₹2,303 Cr | — |
| P/E Ratio | 50.32x | 12.43x |
| P/B Ratio | 8.53x | 1.95x |
| EPS | ₹5.35 | ₹1.38 |
| Book Value | ₹220.79 | ₹58.93 |
| Dividend Yield | 0% | 0.38% |
Growth
| Metric | BETA | QMSMEDI |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -55.53% | -7.96% |
| Qtr Profit Growth | -64.01% | -32.43% |
Profitability & Leverage
| Metric | BETA | QMSMEDI |
|---|---|---|
| ROE | 9.58% | 10.46% |
| ROCE | 14.63% | 8.9% |
| Net Margin | 10.78% | 0% |
| Operating Margin | 13.32% | 13.3% |
| Debt to Equity | 0.87x | 0.65x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BETA | QMSMEDI |
|---|---|---|
| Promoter Holding | 59.1%▼ 5.53 pp | 68.11% |
| FII Holding | 1.02%▼ 0.14 pp | 0% |
| DII Holding | 6.23%▲ 4.08 pp | 1.59% |
| Public Holding | 33.65%▲ 1.59 pp | 30.3% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and QMSMEDI.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.